4 July 2023: Reference is made to the stock exchange release of Vistin Pharma ASA (“Vistin” or the “Company”) dated 30 June 2023 at 07:30 hours CEST concerning an offer to buy back shares (the “Offer”) in connection with its Long Term Incentive Plan (LTIP) for the executive management. The Offer expired Monday 3 July 2023 at 16:00 hours CEST.
The Company has resolved to buy back 220 000 shares at a price of NOK 23,00 per share (the “Purchase Price”). The Purchase Price was determined through a reverse book-building process conducted by SpareBank 1 Markets AS.
As a result of the buy back, the Company owns 220 000 own shares, corresponding to 0,50% of the share capital and voting rights in the Company.
For further information, please contact:
Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN…
BOUCHERVILLE, Québec, June 28, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL, LSL.DB)…
SALINAS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL;…
MINNEAPOLIS, MN, US, June 28, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTC: PETV, PETVW),…
BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or…
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a…